Inotiv (NOTV)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.66 (+16.84%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Inotiv (NOTV)
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.

Key Insights

Critical company metrics and information
  • Share Price

    $3.92
  • Market Cap

    $101.98 Million
  • Total Outstanding Shares

    26.02 Million Shares
  • Total Employees

    2,075
  • Dividend

    No dividend
  • IPO Date

    November 25, 1997
  • SIC Description

    Services-commercial Physical & Biological Research
  • Homepage

    https://www.inotivco.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Operating Activities, Continuing$-6.80 Million
Net Cash Flow$-14.06 Million
Net Cash Flow, Continuing$-13.96 Million
Exchange Gains/Losses$-98,000.00
Net Cash Flow From Financing Activities, Continuing$9.68 Million
Net Cash Flow From Operating Activities$-6.80 Million
Net Cash Flow From Investing Activities, Continuing$-16.83 Million
Net Cash Flow From Investing Activities$-16.83 Million
Net Cash Flow From Financing Activities$9.68 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Basic Earnings Per Share$-4.19
Income/Loss From Continuing Operations After Tax$-108.89 Million
Costs And Expenses$621.50 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Preferred Stock Dividends And Other Adjustments$0.00
Other Operating Expenses$520.03 Million
Net Income/Loss Available To Common Stockholders, Basic$-108.44 Million
Diluted Earnings Per Share$-4.19
Diluted Average Shares$25.90 Million
Income/Loss From Continuing Operations Before Tax$-130.76 Million
Income Tax Expense/Benefit$-21.88 Million
Net Income/Loss Attributable To Parent$-108.44 Million
Benefits Costs and Expenses$621.50 Million
Depreciation and Amortization$57.12 Million
Operating Expenses$577.14 Million
Revenues$490.74 Million
Net Income/Loss$-108.89 Million
Operating Income/Loss$-86.41 Million
Basic Average Shares$25.90 Million
Net Income/Loss Attributable To Noncontrolling Interest$-440,000.00

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Assets$781.36 Million
Noncurrent Liabilities$491.81 Million
Accounts Payable$33.53 Million
Long-term Debt$393.34 Million
Current Assets$163.41 Million
Equity Attributable To Parent$170.50 Million
Other Current Assets$145.24 Million
Current Liabilities$119.04 Million
Liabilities$610.86 Million
Inventory$18.17 Million
Other Current Liabilities$85.52 Million
Other Non-current Liabilities$98.48 Million
Liabilities And Equity$781.36 Million
Fixed Assets$188.33 Million
Equity$170.50 Million
Noncurrent Assets$617.95 Million
Equity Attributable To Noncontrolling Interest$0.00
Other Non-current Assets$429.62 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.